Essais liés7clinical trials
VillePraguelocalisation
PaysCzechialocalisation
SourcelocaleCSV/MySQL

Informations

centre

Synchronisé depuis ClinicalTrials.gov — NCT05001737

Ouvrir le site du centre

Essais cliniques associés

7
MoléculeIndication / populationPhaseNCTTitreStatut
Tacabrutideg Cancer Phase 3 NCT06846671 CaDAnCe-302 — A Study of Tacabrutideg (BGB-16673) Compared to Investigator's Choice in Participants With Chronic Lymphocytic Leukemia or Small Lymphocytic Lymphoma Previously Exposed to Both Bruton Tyrosine Kinase (BTK) and B-cell Leukemia/Lymphoma 2 Protein (BCL2) Inhibitors RECRUITING
Sonrotoclax Cancer Phase 3 NCT07277231 A Study to Investigate Sonrotoclax (BGB-11417) Plus Zanubrutinib (BGB-3111) Compared With Venetoclax Plus Acalabrutinib in Adults With Previously Untreated Chronic Lymphocytic Leukemia RECRUITING
BMS-986368 Myopathies Phase 2 NCT06782490 MSS — A Study to Evaluate the Efficacy, Safety and Tolerability of BMS-986368 in Participants With Multiple Sclerosis Spasticity RECRUITING
Emapalumab Lupus Phase 3 NCT05001737 EMERALD — Evaluate Efficacy, Safety and Tolerability, PK and PD of Emapalumab in Children and Adults With MAS in Still's or SLE COMPLETED
Ocrelizumab SEP Phase 3 NCT05269004 OLERO — A Rollover Study to Evaluate the Long-Term Safety and Efficacy of Ocrelizumab In Patients With Multiple Sclerosis ACTIVE_NOT_RECRUITING
Pegcetacoplan (APL-2) Sclérose latérale amyotrophique Phase 2 NCT04579666 MERIDIAN: A Study to Evaluate the Efficacy and Safety of Pegcetacoplan in Adults With Amyotrophic Lateral Sclerosis (ALS) TERMINATED
CVN424 75 mg Parkinson Phase 3 NCT06553027 To Evaluate the Efficacy of CVN424 in Parkinson's Disease Participants With Motor Complications ACTIVE_NOT_RECRUITING